Nectar Lifesciences has received European approval for its Cephalosporin APIs manufacturing facility at Derabassi in Punjab. Dinesh Dua, chief executive director at Nectar Lifesciences, in an interview to CNBC-TV18, said the API manufacturing facility is likely to boost the company’s revenues by 5-10%.
first published: Oct 14, 2011 02:29 pm
A collection of the most-viewed Moneycontrol videos.
From renewables to AI and SMEs: Madhusudan Kela on where he senses opportunity now
Will The Pre-Diwali Nifty Rally Rage On Amid Weak Global Cues? RIL Q2 in Focus | Opening Bell Live
Infosys Q2 Earnings Live | Decoding Infosys Q2 Earnings | Earnings Express
Indian stocks Vs Gold, Silver, Global equities: Manish Chokhani on where to sow, where to harvest
